Completed PHASE3 INTERVENTIONAL 4-arm NCT02181101

Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial

Sponsor: AstraZeneca

Interventions FEC-Doc adjuvant chemotherapy FEC-DocGemzar adjuvant chemotherapy Zoledronic acid i.v. 2 years Zoledronic acid i.v. 5 years

Updated 5 times since 2017 Last updated: Jul 1, 2014 Started: Sep 30, 2005 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02181101, this PHASE3 trial focuses on Breast Neoplasms and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Chugai Pharma USA
Eli Lilly and Company
Janssen Diagnostics, LLC
Ludwig-Maximilians - University of Munich
Novartis
Sanofi

Data source: Ludwig-Maximilians - University of Munich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany